The present invention relates to a special type of non-internalizing binding moiety- drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to LGALS3BP, said antibody being conjugated to cytotoxic drugs. The invention also comprises methods of the treatment of LGALS3BP-expressing cancer, including administering to a patient the disclosed drug conjugates and pharmaceutical preparations.
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer
Emily CAPONE;Rodolfo Ippoliti;Gianluca Sala
2019-01-01
Abstract
The present invention relates to a special type of non-internalizing binding moiety- drug-conjugates that specifically target LGALS3BP. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to LGALS3BP, said antibody being conjugated to cytotoxic drugs. The invention also comprises methods of the treatment of LGALS3BP-expressing cancer, including administering to a patient the disclosed drug conjugates and pharmaceutical preparations.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
WO2019197651A1.pdf
accesso aperto
Tipologia:
PDF editoriale
Dimensione
3.93 MB
Formato
Adobe PDF
|
3.93 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
